News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Gilead Sciences, Inc. Says U.S. Upholds One Viread Patent
May 21, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LOS ANGELES, May 20 (Reuters) - Gilead Sciences Inc said on Tuesday that U.S. patent officials have upheld one of the four challenged patents covering its AIDS medicine Viread.
Twitter
LinkedIn
Facebook
Email
Print
Legal
Gilead Sciences, Inc.
MORE ON THIS TOPIC
FDA
Unforced errors flummox HHS’ radical transparency bid—again
May 6, 2026
·
6 min read
·
Heather McKenzie
Patents
Pfizer settles with generic drugmakers to protect blockbuster drug until 2031
April 29, 2026
·
2 min read
·
Nick Paul Taylor
Pancreatic cancer
Revolution levels legal threat on Erasca as pancreatic cancer rivalry heats up
April 28, 2026
·
3 min read
·
Tristan Manalac
Drug pricing
Regeneron finally joins Trump’s drug pricing push while notching landmark approval
April 24, 2026
·
2 min read
·
Tristan Manalac
